BioPharma Credit

BioPharma Credit EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of BioPharma Credit (BPCR.L) as of Nov 21, 2026 is 11.29. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was 9.25 — a change of 22.03% (higher).

EV/FCF

11.29

YoY

22.03%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of BioPharma Credit is 2025 11.29 . EV/FCF (Enterprise Value to Free Cash Flow) of BioPharma Credit was 2024 9.25 . It decreases by 22.03% higher compared to the previous year.

The BioPharma Credit EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2018
10.09 USD
Jan 1, 2019
5.66 USD
Jan 1, 2020
14.60 USD
Jan 1, 2021
9.81 USD
Jan 1, 2022
5.00 USD
Jan 1, 2023
7.36 USD
Jan 1, 2024
9.25 USD
Jan 1, 2025
11.29 USD
The BioPharma Credit EV/FCF history
YEAREV/FCFYoY
11.29+22.03%
9.25+25.79%
7.36+47.24%
5.00-49.10%
9.81-32.78%
14.60+157.92%
5.66-43.91%
10.09-66.28%
29.93—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioPharma Credit Stock analysis

What does BioPharma Credit do? BioPharma Credit PLC was founded in 2017 and is an investment company specializing in financing in the biopharmaceutical and medical field. The company's goal is to identify investment opportunities in the rapidly growing biopharmaceutical market and generate lucrative returns for investors. BioPharma Credit's business model is based on providing loans to biotechnology and pharmaceutical companies. These loans are used to finance important projects and research that contribute to the development of new drugs and treatment methods. In return, the companies receive interest payments and loan repayments according to the agreements in the contract. BioPharma Credit pursues a differentiated strategy and invests in various sectors of the biopharmaceutical industry, such as cancer treatments, immunotherapies, or rare diseases. This includes riskier but potentially very profitable projects such as clinical trials or the market entry of new drugs. BioPharma Credit's portfolio currently includes approximately 26 investments in various areas of the biopharmaceutical industry. The company works closely with experienced partners such as the pharmaceutical company Pharmakia or the analysis firm IHS to conduct comprehensive due diligence and carefully assess opportunities and risks. Another important element of BioPharma Credit's business model is the investors. Most of BioPharma Credit's investors are institutional investors such as pension funds or insurance companies. Therefore, the company also takes into account the needs and requirements of these investors in the selection of borrowers and projects. BioPharma Credit offers its investors high transparency and protection against potential risks. All investments are made through a GmbH structure with fixed terms and fixed interest payments. In addition, the portfolio is regularly monitored and adjusted by an expert team to minimize risks and seize opportunities. Overall, BioPharma Credit offers its investors an attractive opportunity to benefit from the opportunities in the rapidly growing biopharmaceutical market without directly entering the risks and challenges of the biopharmaceutical industry. At the same time, BioPharma Credit contributes to driving important innovations and advancements in medicine and thereby generating societal and health benefits. One of BioPharma Credit's most successful investments in recent years, for example, was a loan to the British biotechnology company Orchard Therapeutics. This company specializes in the development of gene therapies for rare diseases. The loan from BioPharma Credit helped Orchard Therapeutics conduct a clinical trial and enter the market. Orchard Therapeutics' gene therapy has since been approved by the European Medicines Agency and has the potential to improve the lives of millions of people worldwide. Overall, the success story of BioPharma Credit demonstrates how investments in the field of biopharmaceuticals and medicine can contribute to driving important innovations and advancements in medicine while also achieving attractive returns for investors. The company has established itself as an experienced and reliable partner that, thanks to its expertise and networks, will continue to identify and realize successful investments in the biopharmaceutical sector in the future. BioPharma Credit is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioPharma Credit stock

EV/FCF (Enterprise Value to Free Cash Flow) of BioPharma Credit is 11.29 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of BioPharma Credit changed from 9.25 to 11.29, representing a 22.03% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) BioPharma Credit since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s BioPharma Credit with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — BioPharma Credit

All Key Metrics — BioPharma Credit